Sumesh Kachroo, PhD

The risk of discontinuation of oral anticoagulant therapy (both warfarin and direct oral anticoagulant therapies [DOACs]) among nonvalvular atrial fibrillation patients was high. Although the hazard ratio for discontinuation favors DOACs, it is unlikely that the small difference in discontinuation relative to warfarin is clinically meaningful.

Many more patient than provider characteristics are associated with optimal or poor glycemic control and treatment intensification when glycemic control is initially lost.